Digestive system tumor is one of the most common life-threatening diseases in the world. Despite the development of various cancer treatments such as chemotherapy, radiotherapy, targeted therapy, and immunotherapy, cancer remains difficult to cure due to the complex mechanisms involved in cancer initiation, progression, metastasis, and drug resistance. As a result, among the therapies currently available, targeted therapy has emerged as the most promising due to its precise positioning therapy, relatively low toxicity, and ease of administration.
However, drug discovery faces economic and scientific imperatives to find and deliver lead compounds quickly and efficiently. Additionally, drug resistance will occur when targeted drugs are used for an extended period of time. As a result, identifying new targets and developing new strategies for digestive system tumor drug discovery and development is critical. With the advancement of bioinformatics, chemical biology, computational chemistry, and other disciplines, a large number of novel anticancer drug targets are emerging that can be used for drug discovery. Furthermore, the paradigm for identifying pharmacologically significant compounds has shifted from largely serendipitous, trial-and-error approaches to much more multifaceted and sophisticated approaches, which has greatly facilitated efficient drug discovery.
We welcome high-quality Original Research articles and Reviews for this Research Topic. The subtopics include, but are not limited to:
1. Investigation and validation of new targets in tumorigenesis and development of digestive system tumors;
2. New strategies for digestive system tumors drug discovery;
3. Target-based drug design;
4. Proteolysis targeting chimera (PROTACs);
5. Drug repositioning;
6. Covalent drug design;
7. ProTide prodrugs;
8. Diversity-Oriented Synthesis (DOS);
9. DNA-encoded chemical library;
10. Mechanism-based drug design.
Please note: Studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied. Quantitative analysis must be performed on a minimum number of 3 biological replicates in order to enable an assessment of significance. Studies that do not comply with these requirements will not be considered for review.
Digestive system tumor is one of the most common life-threatening diseases in the world. Despite the development of various cancer treatments such as chemotherapy, radiotherapy, targeted therapy, and immunotherapy, cancer remains difficult to cure due to the complex mechanisms involved in cancer initiation, progression, metastasis, and drug resistance. As a result, among the therapies currently available, targeted therapy has emerged as the most promising due to its precise positioning therapy, relatively low toxicity, and ease of administration.
However, drug discovery faces economic and scientific imperatives to find and deliver lead compounds quickly and efficiently. Additionally, drug resistance will occur when targeted drugs are used for an extended period of time. As a result, identifying new targets and developing new strategies for digestive system tumor drug discovery and development is critical. With the advancement of bioinformatics, chemical biology, computational chemistry, and other disciplines, a large number of novel anticancer drug targets are emerging that can be used for drug discovery. Furthermore, the paradigm for identifying pharmacologically significant compounds has shifted from largely serendipitous, trial-and-error approaches to much more multifaceted and sophisticated approaches, which has greatly facilitated efficient drug discovery.
We welcome high-quality Original Research articles and Reviews for this Research Topic. The subtopics include, but are not limited to:
1. Investigation and validation of new targets in tumorigenesis and development of digestive system tumors;
2. New strategies for digestive system tumors drug discovery;
3. Target-based drug design;
4. Proteolysis targeting chimera (PROTACs);
5. Drug repositioning;
6. Covalent drug design;
7. ProTide prodrugs;
8. Diversity-Oriented Synthesis (DOS);
9. DNA-encoded chemical library;
10. Mechanism-based drug design.
Please note: Studies consisting solely of bioinformatic investigation of publicly available genomic/transcriptomic/proteomic data do not fall within the scope of the section unless they are expanded and provide significant biological or mechanistic insight into the process being studied. Quantitative analysis must be performed on a minimum number of 3 biological replicates in order to enable an assessment of significance. Studies that do not comply with these requirements will not be considered for review.
